ArticleScientific reports2025
lncRNA RP11-199F11.2 promotes high-grade serous ovarian cancer cell proliferation by regulating cuproptosis through FDX1.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epigenetic regulation of cuproptosis in cancer: mechanisms, microenvironment, and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy.Frontiers in oncology · 2026Review
- Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.Oncology reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To elucidate the expression characteristics of the long noncoding RNA RP11-199F11.2 (RP11) in high-grade serous ovarian cancer (HGSOC) and its potential mechanism of regulating cancer progression via the copper-death pathway, and to evaluate the therapeutic potential of the copper ion carrier ES-Cu. The interaction between RP11 and FDX1 was predicted via bioinformatics; the posttranscriptional inhibition of FDX1 by RP11 was verified via qRT‒PCR and Western blotting; the effects of RP11 knockdown/overexpression on proliferation were evaluated in in vitro and in subcutaneous xenograft cancer models; ES-Cu was used to induce copper death, and cell death patterns and circulating inflammatory cytokines were detected via flow cytometry and ELISA. RP11 was significantly highly expressed in HGSOC tissues and was positively correlated with FIGO stage and lymph node metastasis (P < 0.01). Mechanistically, bioinformatic analysis suggests that RP11 may binds the 3'-UTR of FDX1 to reduce its translation, thereby limiting copper death and increased cell proliferation. ES-Cu treatment restored FDX1 expression, re-activated copper death, and reduced tumour volume by 68% (P < 0.001) without detectable histological toxicity. RP11 is associated with inhibits copper death and modulation of local inflammatory milieu by suppressing FDX1, which may contribute to HGSOC progression. ES-Cu re-activates the FDX1-copper-death axis, providing a potential strategy for combining copper-death induction with immunomodulation in HGSOC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.